Hims & Hers Health (NYSE:HIMS) shares surged this week, closing 13.7% higher after the U.S. Food and Drug Administration (FDA) announced a high-stakes meeting to re-evaluate the regulatory status of several popular peptides.
Arbutus Biopharma (NASDAQ:ABUS), a clinical-stage biopharmaceutical company specializing in chronic infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for imdusiran (AB-729) for the treatment of chronic hepatitis B (cHBV).
Labcorp (NYSE:LH), a global leader in innovative laboratory services, has announced the launch of the Labcorp Fentanyl Urine Visual Test.
Herbalife (NYSE:HLF) announced preliminary financial results for the first quarter of 2026 on Tuesday, reporting that net sales growth and adjusted earnings are expected to surpass the high end of its previously issued guidance.
Nurix Therapeutics (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on small molecule therapies for cancer and immune disorders, reported its first-quarter 2026 financial results and provided a comprehensive update on its lead clinical programs on April 8, 2026.
Priovant Therapeutics, a majority-owned subsidiary of Roivant Sciences (NASDAQ:ROIV), provided a significant update on its late-stage immunology pipeline on Thursday, April 2, 2026.
Immunovant (NASDAQ:IMVT) announced topline results from two Phase 3 clinical studies evaluating batoclimab in patients with active, moderate-to-severe thyroid eye disease (TED) on Thursday, April 2, 2026.
FitLife Brands (NASDAQ:FTLF) announced its financial results for the fourth quarter and full year ended December 31, 2025, on Wednesday, April 1, 2026. The results highlight a transformative period for the Omaha-based company, largely defined by the successful integration and rapid scaling of the Irwin acquisition.
IDEXX Laboratories (NASDAQ:IDXX) announced on Wednesday, April 1, 2026, the official launch of the IDEXX Cancer Dx™ Panel in the United Kingdom.
Cadrenal Therapeutics (NASDAQ:CVKD) reported its fourth-quarter and full-year 2025 financial results on Tuesday, March 31, 2026, marking a critical transition from mid-stage development to pivotal Phase 3 readiness for its lead candidate, CAD-1005.
Keenova Therapeutics (NYSE:MNK) reported robust fourth-quarter and full-year 2025 financial results on Tuesday, marking its first full quarter as a combined branded therapeutics entity following the merger of Mallinckrodt and Endo.
Xtant Medical Holdings (NYSE:XTNT) reported robust financial results for the full year 2025 on Tuesday, marked by double-digit revenue growth and a strategic pivot toward its core orthobiologics business.
